Hoping and praying for encouraging news like this to keep flowing from these conferences:
News just out today, from the big ASCO (American Society of Clinical Oncology) conference going on now, in Chicago: events.jspargo.com/ASCO17/P...
“Abiraterone not only prolonged life, but also lowered the chance of relapse by 70% and reduced the chance of serious bone complications by 50%,” James said. “Based on the magnitude of clinical benefit, we believe the upfront care for patients newly diagnosed with advanced prostate cancer should change.”
"If you have just been diagnosed with metastatic prostate cancer and your doctor wants to start you on ADT (androgen deprivation therapy, such as Lupron), which shuts off the supply of testosterone and other male hormones, ask for abiraterone as well. It could extend your life for years.
But wait, you might be thinking (and your doctor might be telling you): abiraterone, which targets the androgen receptors, is a second-line hormonal therapy drug. It’s supposed to be given if ADT stops working. Or, if ADT stops working, you’re supposed to start chemotherapy with docetaxel. "
-and at the end of June is this conference: prosca.org/
Global Congress on Prostate Cancer
The fifth Global Congress on Prostate Cancer will bring us to Lisbon, Portugal.
During this major educational multidisciplinary event purely focusing on prostate cancer, we invite you to actively contribute in the discussion on how to deal with dilemmas when managing prostate cancer.
28 - 30 June 2017 - Lisbon, Portugal